Literature DB >> 8828879

Opiate-dependent patients receiving methadone. How physicians should manage therapy.

M Kahan1, N Sutton.   

Abstract

Methadone treatment can reduce illicit drug use, needle sharing, and the social costs and health risks of heroin addiction. It is superior to no treatment, detoxification, or treatment programs lasting less than 3 months. For most patients, the optimal methadone dose is 50 to 120 mg daily. Supervised, random urine drug specimens should be collected at least twice weekly. Long-term counseling is essential and should include information on the risks of needle sharing and on screening for HIV and hepatitis B and C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828879      PMCID: PMC2146884     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  36 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  A randomized trial of an interim methadone maintenance clinic.

Authors:  S R Yancovitz; D C Des Jarlais; N P Peyser; E Drew; P Friedmann; H L Trigg; J W Robinson
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

3.  A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV.

Authors:  S Vanichseni; B Wongsuwan; K Choopanya; K Wongpanich
Journal:  Int J Addict       Date:  1991-12

4.  Treating drug problems.

Authors:  D R Gerstein; L S Lewin
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  The use of serum methadone levels in patients receiving methadone maintenance.

Authors:  J Bell; V Seres; P Bowron; J Lewis; R Batey
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

7.  Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients.

Authors:  D M Novick; H Joseph; T S Croxson; E A Salsitz; G Wang; B L Richman; L Poretsky; J B Keefe; E Whimbey
Journal:  Arch Intern Med       Date:  1990-01

8.  Perinatal and developmental outcome of infants exposed to methadone in-utero.

Authors:  K Kaltenbach; L P Finnegan
Journal:  Neurotoxicol Teratol       Date:  1987 Jul-Aug       Impact factor: 3.763

Review 9.  Methadone treatment and acquired immunodeficiency syndrome.

Authors:  J R Cooper
Journal:  JAMA       Date:  1989 Sep 22-29       Impact factor: 56.272

10.  Developmental consequences of prenatal exposure to methadone.

Authors:  S L Hans
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.